关于持股 5%以上股东被动稀释及减持股份比例超过 1%的 公告 证券代码：300858 证券简称：科拓生物 公告编号：2023-073 北京科拓恒通生物技术股份有限公司 2023年8月15日，张列兵通过大宗交易的方式减持公司股份125,600股，减持 持股 5%以上股东张列兵保证向本公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 2022年6月13日，北京科拓恒通生物技术股份有限公司（ 以下简称（ 公司"） 实施的2021年限制性股票激励计划首次授予部分第一个归属期归属条件达成，公 司向22名符合条件的激励对象发行393,600股股票。公司总股本由148,531,845股 增加至148,925,445股。本次股本增加前，张列兵持有公司9,518,042股股份，持股 比例为6.4081%；本次股本增加后，张列兵持有股权比例为6.3911%。 公司于2023年8月2日披露了 关于持股5%以上股东减持股份预披露公告》 公告编号： 2023-070），张列兵计划以集中竞价或大宗交易的方式拟合计减持 公司股份数量不超过7,9 ...

第一创业证券承销保荐有限责任公司 关于北京科拓恒通生物技术股份有限公司 2023 年半年度持续督导跟踪报告 | 保荐机构名称：第一创业证券承销保荐有限责任公司 | 被保荐公司简称：科拓生物 | | --- | --- | | 保荐代表人姓名：刘毅 | 联系电话：010-63212080 | | 保荐代表人姓名：李兴刚 | 联系电话：010-63212080 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于防止 | | | 关联方占用公司资源的制度、募集资金管理制度、内控制 | 是 | | 度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 次 6 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 ...

1、统一社会信用代码：91110116754160123E 证券代码：300858 证券简称：科拓生物 公告编号：2023-072 北京科拓恒通生物技术股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京科拓恒通生物技术股份有限公司（以下简称"公司"）于 2023 年 4 月 17 日召开第二届董事会第二十次会议和 2023 年 5 月 12 日召开的 2022 年年度股东 大会审议通过了《关于变更公司注册资本、修订<公司章程>并办理工商变更登记 的议案》，具体内容详见公司于 2023 年 4 月 19 日刊载于中国证监会指定信息披 露网站巨潮资讯网（www.cninfo.com.cn）上的《关于变更公司注册资本、修订< 公司章程>并办理工商变更登记的公告》（公告编号：2023-037）。 近日，公司已完成工商变更登记及《公司章程》备案手续，并取得北京市怀 柔区市场监督管理局换发的营业执照，变更后的工商登记基本信息如下： 2、名称：北京科拓恒通生物技术股份有限公司 3、类型：股份有限公司（上市、自然人投资或控股） 4、 ...

Financial Performance - The company reported a revenue of RMB 300 million for the first half of 2023, representing a year-on-year increase of 15%[18]. - The net profit attributable to shareholders for the same period was RMB 50 million, up 20% compared to the previous year[18]. - The company's operating revenue for the reporting period was ¥139,931,675.55, a decrease of 10.79% compared to the same period last year[25]. - The net profit attributable to shareholders was ¥40,332,596.67, down 10.01% year-on-year[25]. - The net cash flow from operating activities was ¥45,668,510.07, reflecting a significant decline of 43.66% compared to the previous year[25]. - The basic earnings per share decreased by 25.00% to ¥0.15[25]. - The total assets at the end of the reporting period were ¥1,741,023,160.76, a decrease of 2.77% from the end of the previous year[25]. - The company achieved operating revenue of 139.93 million yuan, a year-on-year decrease of 10.79%[46]. - The net profit attributable to the parent company was 40.33 million yuan, down 10.01% year-on-year[46]. Market Expansion and Product Development - The company plans to launch two new products in Q4 2023, focusing on advanced probiotic formulations[18]. - Future outlook indicates a projected revenue growth of 30% for the full year 2023, driven by market expansion and new product launches[18]. - The company aims to expand its market share in the Asia-Pacific region, targeting a 15% increase in market penetration by the end of 2024[18]. - The company is focusing on developing probiotics suitable for the Chinese gut microbiome, which differs from Western populations[40]. - The company is committed to advancing research and development in the probiotic sector, aiming to meet the growing consumer demand for health-oriented products[41]. - The company is actively involved in setting industry standards for postbiotics, contributing to product quality and food safety[48]. - The company is focusing on enhancing its R&D and production capabilities in response to the growing consumer demand for health products in the probiotics market[124]. Research and Development - Research and development expenses increased by 10%, totaling RMB 30 million, reflecting the company's commitment to innovation[18]. - The company invested 15.12 million yuan in R&D, a year-on-year increase of 37.43%, and obtained 6 new domestic invention patents related to probiotics[47]. - The company holds 86 invention patents related to probiotics, significantly leading the domestic market[85]. - The company has preserved over 20,000 strains in its probiotic strain resource bank, establishing the largest probiotic strain resource bank in Asia as of June 30, 2023[154]. - The company is advancing the development of new probiotic drugs for treating Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) in collaboration with Jiangzhong Pharmaceutical[188]. Strategic Partnerships and Collaborations - The company is exploring potential acquisitions to enhance its product portfolio and market presence[18]. - A strategic cooperation agreement was signed with New Ruipeng Pet Medical Group to enhance the product matrix in the pet probiotics sector[50]. - The company signed a strategic cooperation agreement with Mengniu Dairy for the procurement of thickening agents, with a commitment to maintain a pricing principle that does not exceed 70% of the market price as of December 2020[182]. - The company has established deep R&D collaborations with leading enterprises in the food, pharmaceutical, and daily chemical sectors, enhancing its strategic partnerships[70]. Competitive Landscape - The company faces competition from multinational corporations such as DuPont and Chr. Hansen in the probiotics sector, which poses challenges for market promotion due to brand recognition issues[131]. - The probiotic raw material market is currently dominated by multinational companies, with DuPont and Chr. Hansen holding over 80% market share[40]. Corporate Governance and Management - The company has a stable and experienced management team with extensive industry experience, contributing to its leading position in the compound food additive market[90]. - The company completed the election of the new board of directors and supervisory board on May 12, 2023, with the first meeting of the third board of directors held on the same day[6]. - The company has experienced changes in its board of directors, with new independent directors elected in May 2023[144]. Social Responsibility and Compliance - The company donated 300,000 yuan to the Peking Union Medical College Foundation in March 2023 to support public welfare initiatives in obstetrics[159]. - The company has implemented measures to protect employee rights, including compliance with labor laws and providing social insurance[156]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[153]. Financial Management and Investments - The company reported a significant increase in cash flow from investment activities, with a net outflow of ¥739,994,897.58, up 168.86% year-over-year[95]. - The company has ongoing projects in the food sector, with a cumulative actual investment of 70,188,182.2 yuan and an expected return of 8.20%[111]. - The company has made significant equity investments during the reporting period, although specific details were not disclosed in the provided content[109]. - The company has no derivative investments or entrusted loans during the reporting period, indicating a conservative financial strategy[127][128]. Future Outlook - The company anticipates that the probiotics market will continue to grow rapidly, necessitating further enhancements in its R&D capabilities[124]. - The company plans to expand its market presence and enhance its product offerings through strategic investments and R&D initiatives[119].

编号：2023-001 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □电话会议 □其他 参与单位名称 及人员姓名 科拓生物2022年度业绩说明会采用网络远程方式进行，面向全体投资 者。 时间 2023 年 4 月 27 日 15:00-17:00 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏目 公司接待人员 姓名 董事长：孙天松女士 总经理：刘晓军先生 副总经理、财务总监：余子英先生 副总经理、董事会秘书：张凌宇先生 独立董事：刘惠玉女士 投资者关系活动 主要内容介绍 1、公司最近还有增发计划？资金面紧张？ 答：尊敬的投资者您好，公司提请股东大会授权董事会办理以简易 程序向特定对象发行股票相关事宜尚需公司 2022 年年度股东大会审议， 董事会将根据公司的融资需求在授权期限内审议具体发行方案，报请深 圳证券交易所审核并经中国证监会注册后方可实施，存在不确定性。公 司将及时履行信息披露义务，敬请广大投资者注意投资风险。感谢您的 关注！ 证券代码：300858 证券简称：科拓生物 北京科拓恒通 ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥369.17 million, representing a 1.25% increase compared to ¥364.62 million in 2021[23]. - The net profit attributable to shareholders for 2022 was approximately ¥109.89 million, a slight increase of 0.32% from ¥109.54 million in 2021[23]. - The net profit after deducting non-recurring gains and losses increased by 18.08% to approximately ¥98.08 million in 2022, compared to ¥83.06 million in 2021[23]. - The net cash flow from operating activities for 2022 was approximately ¥148.46 million, marking a significant increase of 34.63% from ¥110.27 million in 2021[23]. - Total assets at the end of 2022 reached approximately ¥1.79 billion, a 72.05% increase from ¥1.04 billion at the end of 2021[23]. - The net assets attributable to shareholders increased by 75.37% to approximately ¥1.70 billion at the end of 2022, compared to ¥967.40 million at the end of 2021[23]. - The company reported a basic earnings per share of ¥0.74 for 2022, unchanged from 2021[23]. - The company achieved a year-on-year revenue growth of 1.25% and a net profit growth of 0.32%, maintaining overall performance stability despite economic pressures[54]. - In 2022, the company's total revenue reached ¥369,165,339.19, with a gross margin of 51.98%, showing a year-on-year increase of 1.25%[72]. - The edible probiotic product business generated revenue of 139.53 million yuan, representing a significant year-on-year growth of 87.09%, driven by increasing consumer awareness of health[88]. - The compound food additive business revenue was 172.70 million yuan, a decline of 27.70% year-on-year, primarily due to market demand fluctuations[90]. Market Position and Strategy - The company aims to increase its market share in the domestic probiotic raw material market, which is currently dominated by foreign brands like DuPont and Chr. Hansen[39]. - The company has a competitive advantage in the domestic market due to its proprietary strains and intellectual property, positioning it well against foreign competitors[40]. - The company is focusing on the development of postbiotics, which are gaining popularity and showing explosive growth potential in the health industry[40]. - The company aims to become "China's leading probiotic brand and a leader in food ingredients," focusing on a comprehensive probiotic product chain[54]. - The company is actively expanding its C-end business, focusing on differentiated marketing strategies across various channels[89]. - The company is focused on expanding its market presence and enhancing its product offerings, particularly in the field of food additives and biotechnology[182]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of CNY 500 million allocated for this purpose[184]. Research and Development - The company invested 22.09 million yuan in R&D, conducting 39 projects and obtaining 7 new domestic invention patents during the reporting period[91]. - The company has established a large lactic acid bacteria resource library with over 20,000 strains, including more than 120 industrialized probiotic strains[81]. - The company is actively engaged in product and technology development, leveraging its strain resource library and R&D platform for continuous innovation[66]. - The company is focusing on improving the flavor and stability of its products through technological advancements in fermentation processes[112]. - The company is enhancing its research and development efforts to adapt to industry demands and improve product offerings, including yogurt fermentation agents and postbiotics[150]. - The company has completed the screening of strains for a new mouthwash-specific lactic acid bacteria product, expanding its product line[113]. - The company is developing a composite probiotic product for the auxiliary treatment of type 2 diabetes, with clinical efficacy confirmed[113]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements and future plans[4]. - The company faces various risks and has outlined measures to address them in the management discussion section[4]. - The company is addressing high customer concentration risks by diversifying its revenue sources into plant protein beverages and baked goods[155]. Corporate Governance - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, and operations, ensuring a complete business system[172]. - The company has an independent financial accounting system and does not share bank accounts with its controlling shareholders[173]. - The company has implemented a restricted stock incentive plan, with key executives receiving allocations of 24,000 shares each for Ma Jie, Yu Ziying, and Zhang Lingyu, and 38,400 shares for Qimu Gesu and Zhang Jianjun[178]. - The company has appointed independent directors to ensure governance and oversight, with each receiving CNY 100,000[194]. - The company continues to expand its management team with experienced professionals from various sectors[195]. - The company has a structured remuneration decision-making process involving shareholder and board approvals[193]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 30% based on new product launches and market expansion strategies[165]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[165]. - The company aims to launch three new products in 2023, which are expected to contribute an additional 200 million RMB in revenue[165]. - The company plans to increase its marketing budget by 30% in 2023 to strengthen brand presence and customer engagement[184].

北京科拓恒通生物技术股份有限公司 2023 年第一季度报告 证券代码：300858 证券简称：科拓生物 公告编号：2023-032 北京科拓恒通生物技术股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | (%) | | 营业收入(元) | 72,147,839.92 | 86.068.078.55 | -16.17% | | 归属于上市公司股东的净利 | 20.051.536.52 | 23.445.594.81 | -14.48% | | 润(元) | | | | | 归属于上市公司股东的扣除 非经常性损益的净利润 | 17.722.508.42 | 19.554.907.86 | -9.37% | | (元) | | | | | 经营 ...

证券代码：300858 证券简称：科拓生物 公告编号：2023-034 为进一步提高公司治理水平，便于广大投资者更全面、深入地了解公司情况， 公司定于2023年4月27日（星期四）下午15:00—17:00在深圳证券交易所"互动易" 平台"云访谈"栏目举行2022年年度报告网上业绩说明会（以下简称"本次说明 会"），现将有关事项公告如下： 本次说明会将采用网络远程的方式举行，投资者可登陆深圳证券交易所"互 动易"平台（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次会议。 出席本次业绩说明会的人员有：公司董事长孙天松女士，总经理刘晓军先生， 副总经理、财务总监余子英先生，副总经理、董事会秘书张凌宇先生，独立董事 刘惠玉女士。 为充分尊重投资者、提升交流的针对性，现就公司本次说明会提前向投资者 公开征集问题。投资者可提前登录"互动易"平台（http://irm.cninfo.com.cn）"云 访谈"栏目进入公司本次说明会页面进行提问。届时公司将在本次说明会上对投 资者普遍关注的问题进行回答。期间，投资者仍可登陆活动界面进行互动提问。 北京科拓恒通生物技术股份有限公司 关于举行 2 ...

Financial Performance - Revenue and non-GAAP net profit increased in the first half of the year, but net profit slightly decreased due to the impact of the pandemic [2][3] - Non-recurring gains and losses decreased in the first half, but recovery began in May and is not expected to affect annual performance [2][3] Strategic Partnerships - The strategic cooperation agreement with Mengniu is expected to be renewed for another three years by the end of the year [3] - The company has partnered with Jiangzhong Pharmaceutical and Shangyao Xinyi for its probiotic business [3] Product Development and Market Strategy - The company's Jinhua Galaxy strain factory meets the production conditions for health supplements, and the company has started laying out in this area [3] - The company is focusing on both B2B and B2C markets for its probiotic business, leveraging partnerships with large food and pharmaceutical companies for B2C product development [4] - The company is conducting clinical trials and research to back the efficacy of its probiotic products [4] Operational Details - The company implements a policy of payment before delivery for its probiotic products sold through offline distributors [4] - Some R&D personnel hold shares in the company through partnerships [4] - The Beijing compound food additive factory has a designed single-shift capacity of 3,500 tons, with the ability to increase shifts to meet demand [4] Industry Insights - Developing probiotic strains requires significant investment in time and resources, and internationally recognized strains have undergone extensive research and clinical trials [3][4]

Group 1: Company Overview and Market Position - The company has been focusing on the research and development of probiotics, particularly in the area of Helicobacter pylori, which has gained significant market attention recently [2][3] - Since its establishment, the company has relied on its proprietary strain resources and has conducted over 50 clinical trials in collaboration with top-tier hospitals, with 29 trials completed [3] - The company aims to achieve technological breakthroughs and deliver products that benefit consumers and society [3] Group 2: Product Development and Clinical Trials - The company has identified several key probiotic strains, including Lactobacillus Zhang and Bifidobacterium V9, and has validated their beneficial functions through large-scale clinical trials [3] - The company has expanded into the probiotic pharmaceutical sector since 2019, elevating its research efforts [3] - The focus on Helicobacter pylori will continue, with ongoing product design and research efforts [3] Group 3: Investor Insights and Market Growth - The company believes it is on par with international probiotic companies in terms of research and development, despite starting later [3] - The domestic probiotic market is experiencing rapid growth, with significant market share still held by multinational corporations [3] - As the only publicly listed probiotic company in China, the company is confident in the future growth of its probiotic product segment [3]